DE2504331A1 - Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung - Google Patents
Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendungInfo
- Publication number
- DE2504331A1 DE2504331A1 DE19752504331 DE2504331A DE2504331A1 DE 2504331 A1 DE2504331 A1 DE 2504331A1 DE 19752504331 DE19752504331 DE 19752504331 DE 2504331 A DE2504331 A DE 2504331A DE 2504331 A1 DE2504331 A1 DE 2504331A1
- Authority
- DE
- Germany
- Prior art keywords
- heptaminol
- adenosine monophosphate
- compound
- therapeutic use
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 title claims description 9
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 title claims description 3
- LREQLEBVOXIEOM-UHFFFAOYSA-N 6-amino-2-methyl-2-heptanol Chemical compound CC(N)CCCC(C)(C)O LREQLEBVOXIEOM-UHFFFAOYSA-N 0.000 title description 9
- 229960005402 heptaminol Drugs 0.000 title description 9
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 title description 2
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000033042 Somatoform disorder cardiovascular Diseases 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 210000005069 ears Anatomy 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000009157 neurocirculatory asthenia Diseases 0.000 claims description 2
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000003748 coronary sinus Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000036450 inotropism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7404237A FR2260331B1 (enrdf_load_stackoverflow) | 1974-02-08 | 1974-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2504331A1 true DE2504331A1 (de) | 1975-08-14 |
Family
ID=9134659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752504331 Withdrawn DE2504331A1 (de) | 1974-02-08 | 1975-02-03 | Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3993639A (enrdf_load_stackoverflow) |
| JP (1) | JPS5630360B2 (enrdf_load_stackoverflow) |
| BE (1) | BE824840A (enrdf_load_stackoverflow) |
| CH (1) | CH597255A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2504331A1 (enrdf_load_stackoverflow) |
| ES (1) | ES434510A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2260331B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1490016A (enrdf_load_stackoverflow) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT84874B (pt) * | 1987-05-15 | 1992-07-31 | Sarget Lab | Processo para a producao de adenosina-5'-monofosfato de heptaminol por atomizacao de uma solucao aquosa que o contem |
| DE69330485T2 (de) * | 1992-10-09 | 2001-12-13 | Canon K.K., Tokio/Tokyo | Magnetkopf für magnetooptische Aufzeichnung und magnetooptisches Aufzeichnungsgerät |
| SE9401499D0 (sv) * | 1994-05-02 | 1994-05-02 | Item Dev Ab | New method of treatment |
| UA28064C2 (uk) * | 1996-12-26 | 2000-10-16 | Акціонерне Товариство Закритого Типу "Фармацевтична Фірма Млк" | Калієві солі різнолігандних координаційних сполук магнію з гістидином і аденозин-5'-трифосфатом або креатинфосфатом, що проявляють захисну дію на міокард від ішемічного ушкодження |
| EP1554572B1 (en) | 2001-07-25 | 2009-10-14 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| JP2005104895A (ja) * | 2003-09-30 | 2005-04-21 | Nippon Kayaku Co Ltd | 光学活性なアミノアルコール化合物の製造法 |
| WO2005074946A1 (en) * | 2004-02-10 | 2005-08-18 | Adenobio N.V. | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases |
| JP2008539047A (ja) | 2005-04-28 | 2008-11-13 | プロテウス バイオメディカル インコーポレイテッド | ファーマインフォーマティックスシステム |
| WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
| AU2010216512B2 (en) | 2009-02-20 | 2016-06-30 | 2-Bbb Medicines B.V. | Glutathione-based drug delivery system |
| CA2760945A1 (en) | 2009-05-06 | 2010-11-11 | Laboratory Skin Care, Inc. | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2710860A (en) * | 1947-10-10 | 1955-06-14 | Physiclogical Chemicals Compan | Nikethamide adenylate |
| FR1292979A (fr) * | 1961-02-08 | 1962-05-11 | Commissariat Energie Atomique | Procédé et appareil pour le traitement de l'eau pure |
| FR4822M (enrdf_load_stackoverflow) * | 1965-04-14 | 1967-02-13 | ||
| US3438968A (en) * | 1966-06-23 | 1969-04-15 | Int Chem & Nuclear Corp | Substituted ammonium basic addition salts of ribonucleic acid |
| BE755361A (fr) * | 1969-08-28 | 1971-03-01 | Newport Pharmaceuticals | Derives de l'inosine |
| JPS4886869A (enrdf_load_stackoverflow) * | 1972-02-23 | 1973-11-15 |
-
1974
- 1974-02-08 FR FR7404237A patent/FR2260331B1/fr not_active Expired
-
1975
- 1975-01-27 BE BE152760A patent/BE824840A/xx not_active IP Right Cessation
- 1975-01-28 CH CH106975A patent/CH597255A5/xx not_active IP Right Cessation
- 1975-02-03 DE DE19752504331 patent/DE2504331A1/de not_active Withdrawn
- 1975-02-05 US US05/547,431 patent/US3993639A/en not_active Expired - Lifetime
- 1975-02-06 ES ES434510A patent/ES434510A1/es not_active Expired
- 1975-02-06 JP JP1614875A patent/JPS5630360B2/ja not_active Expired
- 1975-02-07 GB GB5266/75A patent/GB1490016A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2260331A1 (enrdf_load_stackoverflow) | 1975-09-05 |
| JPS50107121A (enrdf_load_stackoverflow) | 1975-08-23 |
| US3993639A (en) | 1976-11-23 |
| FR2260331B1 (enrdf_load_stackoverflow) | 1978-01-13 |
| ES434510A1 (es) | 1977-03-16 |
| GB1490016A (en) | 1977-10-26 |
| CH597255A5 (enrdf_load_stackoverflow) | 1978-03-31 |
| JPS5630360B2 (enrdf_load_stackoverflow) | 1981-07-14 |
| BE824840A (fr) | 1975-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3438455A1 (de) | L-lysin- und l-histidinpyruvat | |
| DE2504331A1 (de) | Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung | |
| DE2241742B2 (de) | Verwendung von Hydroxyprolinderivaten bei der äußerlichen Behandlung von Bindegewebserk rankungen | |
| DE60108784T2 (de) | Injektionslösung mit entzündungshemmender wirkung und verfahren zu ihrer herstellung | |
| DE3130912A1 (de) | Analgetische arzneimittelkombination | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE69307895T2 (de) | Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin | |
| DE3832401A1 (de) | Pharmazeutische zubereitung zur behandlung entzuendeter nasenschleimhaeute | |
| DE3619426A1 (de) | Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion | |
| DE3212909C2 (enrdf_load_stackoverflow) | ||
| DE1915497A1 (de) | Arzneimittel mit hypolipidaemischer und hypocholesterinaemischer Wirksamkeit | |
| DE68905082T2 (de) | Virushemmende pharmazeutische zusammensetzung. | |
| DE1043587B (de) | Verfahren zur Herstellung eines Appetitzueglers | |
| DE2817923A1 (de) | Septacidinverbindungen und diese enthaltende arzneimittel | |
| DE951228C (de) | Verfahren zur Stabilisierung eines adrenocorticotropen Praeparates | |
| DE2924077C2 (enrdf_load_stackoverflow) | ||
| DE3046927A1 (de) | 8-dialkylaminoalkylaether-coffein-platin-komplexe , verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE3486237T2 (de) | Herstellung von Diacetoxybenzylidendiacetaten. | |
| DE2708666C3 (de) | Arzneimittel mit immunoregulativer und antiphlogistischer Wirkung | |
| DE2518509B2 (de) | Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin | |
| DE2048547C3 (de) | Krampflösend wirkendes pharmazeutisches Mittel | |
| EP0352652B1 (de) | Verwendung von Imexon als Immunsuppressivum | |
| DE2256538C2 (de) | Probenecidsalz des Pivaloyloxymethylesters von D-(-)-α-Aminobenzylpenicillin, seine Herstellung und diese enthaltende pharmazeutische Mittel | |
| EP0078469B1 (de) | Neue pharmazeutische Zusammensetzung | |
| DE3511236A1 (de) | Praeparat mit synergistischer bronchienerweiternder wirkung und verfahren zu dessen herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8130 | Withdrawal |